- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04536038
Framing Clinical Trial Enrollment for Patients With Peripheral Artery Disease
The Effect of opt-in Versus Opt-out Framing on Clinical Trial Enrollment Among Patients With Peripheral Artery Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The GAMEPAD study is a two-arm randomized controlled trial aimed at evaluating whether a home-based walking program with automated coaching augmented with gamification and behavioral economic principles improves functional capacity in patients with PAD. GAMEPAD will be conducted using the Way to Health platform, and patients will enroll and consent for participation online, with available help from a study coordinator by telephone. The present study will leverage the GAMEPAD enrollment process to test whether opt-in or opt-out framing of study participation upon initial contact affects the proportion of patients who ultimately enroll in the GAMEPAD study and the demographic characteristics of enrolled patients.
Eligible patients will be contacted via email to determine their interest in participation in the GAMEPAD study. Patients will be randomized 3:1 to an email message framing trial participation in a standard opt-in manner versus an email message framing trial participation in an opt-out manner.
Patients randomized to opt-in framing will be instructed to visit the Way to Health website to enroll in the GAME PAD study, or to call or email the study coordinator with questions or for assistance in enrolling. Patients randomized to opt-out framing will be informed that a study coordinator will be calling them in the coming days to discuss enrollment in the study.
Baseline characteristics of patients randomized to each framing method will be abstracted from the electronic health record and Penn Data Store, and will include age, sex, race/ethnicity, and medical comorbidities. Whether contacted patients created an account on the Way to Health website and/or ultimately consented for enrollment in the study will be captured.
For all outcomes, we will compare patients initially presented with study participation via opt-in framing versus opt-out framing. The primary outcome will be the proportion of patients that enroll in the GAMEPAD study. We will also report the proportion of enrolled patients that failed to complete the GAMEPAD study among those patients that ultimately enrolled.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least 18 years of age
- Have been seen in the University of Pennsylvania Health System
- Have an ICD-10 code consistent with peripheral artery disease (I70.2x, I70.3x-I70.7x, I73.9) or peripheral artery disease on their problem list
- Have an email address on file with the University of Pennsylvania Health System
Exclusion Criteria:
- Previously indicated unwillingness to be contacted by email for participation in research studies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Opt-in
Patients randomized to opt-in framing will be instructed to visit the Way to Health website to enroll in the study, or to call or email the study coordinator with questions or for assistance in enrolling.
|
|
Experimental: Opt-out
Patients randomized to opt-out framing will receive an email that frames participation in the study as part of the standard of care, and will be informed that a study coordinator will be calling them in the coming days to start enrollment in the study unless they opt out of participation.
|
A study coordinator will call the patient unless they opt-out.
See arm description for more details.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Enrollment in GAMEPAD intervention study
Time Frame: 6 Months
|
The proportion of patients that enroll in the GAMEPAD intervention study
|
6 Months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants that fail to complete study
Time Frame: 12 months
|
The proportion of patients enrolled in GAMEPAD that failed to complete the study
|
12 months
|
Change in step count from baseline to end of intervention
Time Frame: 16 weeks
|
Change in daily step count from baseline to the end of the GAMEPAD intervention (overall and stratified by overall GAME PAD study arm -gamification intervention versus attention control)
|
16 weeks
|
Change in step count from baseline to end of follow-up period
Time Frame: 24 weeks
|
Change in daily step count from baseline to the end of follow-up (overall and stratified by overall GAMEPAD study arm -gamification intervention versus attention control)
|
24 weeks
|
Change in patient-reported symptom scores from baseline to end of GAMEPAD intervention
Time Frame: 16 weeks
|
Change in patient-reported symptom scores from baseline to the end of the GAME PAD intervention (overall and stratified by overall GAMEPAD study arm).
The Walking Impairment Questionnaire will be used to rate the degree of difficulty of various physical activities, ranging from 0 (unable) to 4 (no difficulty).
Scores are divided by the maximum number of points and presented on a scale of 0%-100% where 0% indicates they are unable to do the activity and 100% indicates they have no difficulty.
|
16 weeks
|
Change in patient-reported symptom scores from baseline to end of follow-up period
Time Frame: 24 weeks
|
Change in patient-reported symptom scores from baseline to the end of follow-up (overall and stratified by overall GAMEPAD study arm).
The Walking Impairment Questionnaire will be used to rate the degree of difficulty of various physical activities, ranging from 0 (unable) to 4 (no difficulty).
Scores are divided by the maximum number of points and presented on a scale of 0%-100% where 0% indicates they are unable to do the activity and 100% indicates they have no difficulty.
|
24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alexander Fanaroff, MD, MHS, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 842681
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Artery Disease
-
Janssen Scientific Affairs, LLCHCA Research Institute, LLCRecruitingCoronary Artery Disease (CAD) | Peripheral Artery Disease (PAD)United States
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedStructural Heart Disease | Obstructive Coronary Artery Disease | Obstructive Peripheral Artery DiseaseUnited States
-
Michael Lichtenberg, MDCompletedPeripheral Artery Disease (PAD)Germany
-
Helsinki University Central HospitalCompletedPeripheral Artery Occlusive Disease | Peripheral Artery Stenosis | Peripheral Artery RestenosisFinland
-
Fangge DengRecruitingPeripheral Artery Disease (PAD)China
-
Fundacion para la Formacion e Investigacion Sanitarias...Not yet recruiting
-
Rontis Hellas SAPharmassist LtdActive, not recruitingPeripheral Artery Disease (PAD)Greece
-
Seung-Whan Lee, M.D., Ph.D.Active, not recruitingCatheterization, Peripheral | Popliteal Artery | Angioplasty, Balloon | Femoral ArteryKorea, Republic of
-
Boston Scientific CorporationCompletedAtherosclerosis | Peripheral Artery Disease | Plaque, Atherosclerotic | Artery Diseases, Peripheral | Occlusive Arterial DiseaseUnited States, Belgium, Canada, Japan, Austria, New Zealand
Clinical Trials on Opt-out
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedHepatocellular Carcinoma | CirrhosisUnited States
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA)CompletedSmoking CessationUnited States
-
University of PennsylvaniaCompletedCancer of the Colon
-
University of PennsylvaniaCompletedHypertensionUnited States
-
Johns Hopkins Bloomberg School of Public HealthMakerere University; Pontificia Universidad Javeriana; The Bloomberg Family Foundation...CompletedUse of Consent Language and Mode to Improve Interactive Voice Response Survey in Colombia and UgandaNoncommunicable Diseases | Surveys and QuestionnairesColombia, Uganda
-
University of OklahomaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes... and other collaboratorsCompleted
-
VA Puget Sound Health Care SystemNot yet recruiting
-
Children's Hospital Medical Center, CincinnatiUniversity of UtahNot yet recruitingHIV InfectionsUnited States
-
Denver Health and Hospital AuthorityCompleted